首页> 外文期刊>Chimie Nouvelle >Medicinal Chemistry of Cb1 Cannabinoid eceptor Antagonists
【24h】

Medicinal Chemistry of Cb1 Cannabinoid eceptor Antagonists

机译:Cb1大麻素受体拮抗剂的药物化学

获取原文
获取原文并翻译 | 示例
       

摘要

The long history of Cannabis use has resulted in the development of cannabinoid receptor agonist drugs,such as tetra-hydrocannabinol (DELTA~9-THC,dronabinol)(Figure 1),which have a stimulatory effect on appetite. Only within the past 15 years the research efforts in the cannabinoid area have resulted in the crucial discovery of the endocannabinoid system [1]which comprises to date of two characterized and cloned G-protein-coupled cannabinoid receptors CB_1 and CB_2,five endogenous polyunsatu-rated lipid-like ligands (the so-called endocannabinoids)and the enzymes involved in their formation and breakdown,such as fatty acid amide hydrolase (FAAH)and monoglyceride lipase.
机译:大麻的悠久使用历史导致了大麻素受体激动剂药物的开发,例如四氢大麻酚(DELTA〜9-THC,dronabinol)(图1),它对食欲具有刺激作用。仅在过去15年中,在大麻素领域的研究工作才导致对内源性大麻素系统的关键发现[1],该系统迄今包括两个已鉴定并克隆的G蛋白偶联大麻素受体CB_1和CB_2,五个内源性多不饱和糖-脂质类配体(所谓的内源性大麻素)及其参与形成和分解的酶,例如脂肪酸酰胺水解酶(FAAH)和甘油单酸酯脂肪酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号